Toggle light / dark theme

Hackernews #1 @Rosebud_AI We’re building a platform to help users go from description to code to game. We aim to make game creation accessible to non-technical creators, so our UI provides explanations alongside the generated code.


Users have created a diverse range of games on Rosebud, including top-down RPGs, AI companions, and 3D obstacle courses, all within a few hours and sometimes minutes. Here are some examples you can play and clone (to start your own project).

* Anime Jester Companion: https://play.rosebud.ai/games/ba438cc4-246e-432e-b170-4e16948cd571 * Chat and Care for your Digital Puppy: https://play.rosebud.ai/games/f32a8159-7acf-4db6-a82c-70296f90bbf1 * Sphere Sync (3D game: align the sphere with the right color): https://play.rosebud.ai/games/96dfd5e1-62d4-47d8-a3e9-11038c8bb5cf * Basketball: https://play.rosebud.ai/games/a0e70622-e923-4517-8c1f-728dcf0db486 * Neon Waltz Generative Art: https://play.rosebud.ai/games/e32bd12b-7cc9-4f9a-b385-42ae0b096466 * Chat with Deku from My Hero Academia: https://play.rosebud.ai/games/716fd998-aab6-4185-8375-85d9eeb2adca

A simple way to think about Rosebud is ChatGPT + Midjourney + Replit. ChatGPT, because we give users a chat interface for this code editor so they can describe the game they want to make and generate game code; Midjourney, because we let users generate assets inside Rosebud, 2D and 3D, to be used in their games; And Replit, because Rosebud includes a browser based code editor that lets you deploy your game instantly.

In this episode, Peter and Elon hop on X Spaces to discuss Data-driven optimism, solving grand challenges, uplifting humanity, Digital Super Intelligence, Longevity, Education, and Abundance in 2024.

Elon Musk is a businessman, founder, investor, and CEO. He co-founded PayPal, Neuralink and OpenAI; founded SpaceX, and is the CEO of Tesla and the Chairman of X.

Listen to spaces on X: https://x.com/PeterDiamandis/status/1742713338549997884?s=20

Samsung Electronics has started the development of its “Smart Sensing System,” which is designed to improve yields and transform the way its semiconductor fabs operate. The system is primarily designed to monitor and analyze the production process in real time and currently can automatically handle plasma uniformity. Eventually, Samsung plans to make its fabs fully automated and free of human labor by 2030, reports DigiTimes, citing ET News.

Samsung’s ultimate goal is to have fully unmanned semiconductor production facilities by 2030. Achieving this will require developing systems that can manage large amounts of data and optimize equipment performance automatically. The Smart Sensing System is an important part of this plan and is expected to play a crucial role in making these intelligent, fully automated fabs a reality. Samsung is currently investing tens of millions of won into projects like smart sensors, hoping that its investments will pay off in the long run.

(Nanowerk News) A hardware accelerator initially developed for artificial intelligence operations successfully speeds up the alignment of protein and DNA molecules, making the process up to 10 times faster than state-of-the-art methods.

This approach can make it more efficient to align protein sequences and DNA for genome assembly, which is a fundamental problem in computational biology.

This short video provides:
1. Definition of an AI hallucination.
2. Probability of an AI hallucination occurrence.
3. Top reasons for an AI to hallucinate.

A longer companion video on AI errors or hallucination is also posted. This video goes into more detail on hallucinations plus adds:
1. How to detect an AI hallucination.
2. How to reduce the probability of an AI hallucination.

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”